Pharmacological and clinical properties of levocabastine hydrochloride (eye drop and nasal spray), a selective H1 antagonist

Megumi Akiyoshi, Tsunehiko Shigeoka, Shinichi Torii, Eiji Maki, Satoru Enomoto, Hiromasa Takahashi, Fumiya Hirano

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Levocabastine is a selective histamine H1-receptor antagonist exerting inhibitory effects on the release of chemical mediators from mast cells and on the chemotaxis of polymorphonuclear leukocytes and eosinophils. Both histamine and antigens induced conjunctivitis was inhibited by levocabastine in several allergy models. Levocabastine moderately inhibited histamine-release from guinea pig conjunctive induced by antigen-antibody reactions and prevented an increase in the vascular permeability of the conjunctive elicited by both histamine and antigen instillation. Symptoms of allergic rhinitis, which were induced by histamine, substance P and antigen, were also reduced by levocabastine. Levocabastine prevented an increase in the vascular permeability of nasal mucosa elicited by instillation of these three inducers. Furthermore, levocabastine has shown a large difference between the antiallergic dose and other non-specific pharmacological effective dose than that with other antiallergic drugs. The non-specific pharmacological effect of levocabastine reveals only blepharoptosis. With these pharmacological effects and topical usage, levocabastine was shown to be useful for allergic conjunctive and rhinitis in both seasonal and perennial clinical use.

Original languageEnglish
Pages (from-to)175-184
Number of pages10
JournalFolia Pharmacologica Japonica
Volume119
Issue number3
DOIs
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

levocabastine
Nasal Sprays
Ophthalmic Solutions
Pharmacology
Histamine
Anti-Allergic Agents
Capillary Permeability
Antigens
Blepharoptosis
Histamine H1 Antagonists
Antigen-Antibody Reactions
Conjunctivitis
Nasal Mucosa
Histamine Release
Chemotaxis
Substance P
Eosinophils
Mast Cells

Keywords

  • Allergic conjunctive
  • Allergic rhinitis
  • H antagonist
  • Levocabastine
  • Livostin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pharmacological and clinical properties of levocabastine hydrochloride (eye drop and nasal spray), a selective H1 antagonist. / Akiyoshi, Megumi; Shigeoka, Tsunehiko; Torii, Shinichi; Maki, Eiji; Enomoto, Satoru; Takahashi, Hiromasa; Hirano, Fumiya.

In: Folia Pharmacologica Japonica, Vol. 119, No. 3, 2002, p. 175-184.

Research output: Contribution to journalArticle

Akiyoshi, Megumi ; Shigeoka, Tsunehiko ; Torii, Shinichi ; Maki, Eiji ; Enomoto, Satoru ; Takahashi, Hiromasa ; Hirano, Fumiya. / Pharmacological and clinical properties of levocabastine hydrochloride (eye drop and nasal spray), a selective H1 antagonist. In: Folia Pharmacologica Japonica. 2002 ; Vol. 119, No. 3. pp. 175-184.
@article{521efb5881e447b68e2b69748d2e3368,
title = "Pharmacological and clinical properties of levocabastine hydrochloride (eye drop and nasal spray), a selective H1 antagonist",
abstract = "Levocabastine is a selective histamine H1-receptor antagonist exerting inhibitory effects on the release of chemical mediators from mast cells and on the chemotaxis of polymorphonuclear leukocytes and eosinophils. Both histamine and antigens induced conjunctivitis was inhibited by levocabastine in several allergy models. Levocabastine moderately inhibited histamine-release from guinea pig conjunctive induced by antigen-antibody reactions and prevented an increase in the vascular permeability of the conjunctive elicited by both histamine and antigen instillation. Symptoms of allergic rhinitis, which were induced by histamine, substance P and antigen, were also reduced by levocabastine. Levocabastine prevented an increase in the vascular permeability of nasal mucosa elicited by instillation of these three inducers. Furthermore, levocabastine has shown a large difference between the antiallergic dose and other non-specific pharmacological effective dose than that with other antiallergic drugs. The non-specific pharmacological effect of levocabastine reveals only blepharoptosis. With these pharmacological effects and topical usage, levocabastine was shown to be useful for allergic conjunctive and rhinitis in both seasonal and perennial clinical use.",
keywords = "Allergic conjunctive, Allergic rhinitis, H antagonist, Levocabastine, Livostin",
author = "Megumi Akiyoshi and Tsunehiko Shigeoka and Shinichi Torii and Eiji Maki and Satoru Enomoto and Hiromasa Takahashi and Fumiya Hirano",
year = "2002",
doi = "10.1254/fpj.119.175",
language = "English",
volume = "119",
pages = "175--184",
journal = "Nihon yakurigaku zasshi. Folia pharmacologica Japonica",
issn = "0015-5691",
publisher = "Japanese Pharmacological Society",
number = "3",

}

TY - JOUR

T1 - Pharmacological and clinical properties of levocabastine hydrochloride (eye drop and nasal spray), a selective H1 antagonist

AU - Akiyoshi, Megumi

AU - Shigeoka, Tsunehiko

AU - Torii, Shinichi

AU - Maki, Eiji

AU - Enomoto, Satoru

AU - Takahashi, Hiromasa

AU - Hirano, Fumiya

PY - 2002

Y1 - 2002

N2 - Levocabastine is a selective histamine H1-receptor antagonist exerting inhibitory effects on the release of chemical mediators from mast cells and on the chemotaxis of polymorphonuclear leukocytes and eosinophils. Both histamine and antigens induced conjunctivitis was inhibited by levocabastine in several allergy models. Levocabastine moderately inhibited histamine-release from guinea pig conjunctive induced by antigen-antibody reactions and prevented an increase in the vascular permeability of the conjunctive elicited by both histamine and antigen instillation. Symptoms of allergic rhinitis, which were induced by histamine, substance P and antigen, were also reduced by levocabastine. Levocabastine prevented an increase in the vascular permeability of nasal mucosa elicited by instillation of these three inducers. Furthermore, levocabastine has shown a large difference between the antiallergic dose and other non-specific pharmacological effective dose than that with other antiallergic drugs. The non-specific pharmacological effect of levocabastine reveals only blepharoptosis. With these pharmacological effects and topical usage, levocabastine was shown to be useful for allergic conjunctive and rhinitis in both seasonal and perennial clinical use.

AB - Levocabastine is a selective histamine H1-receptor antagonist exerting inhibitory effects on the release of chemical mediators from mast cells and on the chemotaxis of polymorphonuclear leukocytes and eosinophils. Both histamine and antigens induced conjunctivitis was inhibited by levocabastine in several allergy models. Levocabastine moderately inhibited histamine-release from guinea pig conjunctive induced by antigen-antibody reactions and prevented an increase in the vascular permeability of the conjunctive elicited by both histamine and antigen instillation. Symptoms of allergic rhinitis, which were induced by histamine, substance P and antigen, were also reduced by levocabastine. Levocabastine prevented an increase in the vascular permeability of nasal mucosa elicited by instillation of these three inducers. Furthermore, levocabastine has shown a large difference between the antiallergic dose and other non-specific pharmacological effective dose than that with other antiallergic drugs. The non-specific pharmacological effect of levocabastine reveals only blepharoptosis. With these pharmacological effects and topical usage, levocabastine was shown to be useful for allergic conjunctive and rhinitis in both seasonal and perennial clinical use.

KW - Allergic conjunctive

KW - Allergic rhinitis

KW - H antagonist

KW - Levocabastine

KW - Livostin

UR - http://www.scopus.com/inward/record.url?scp=0036221894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036221894&partnerID=8YFLogxK

U2 - 10.1254/fpj.119.175

DO - 10.1254/fpj.119.175

M3 - Article

C2 - 11915520

AN - SCOPUS:0036221894

VL - 119

SP - 175

EP - 184

JO - Nihon yakurigaku zasshi. Folia pharmacologica Japonica

JF - Nihon yakurigaku zasshi. Folia pharmacologica Japonica

SN - 0015-5691

IS - 3

ER -